Moderna Inc. (NASDAQ:MRNA) announced changes to its operating model and leadership structure. The biotechnology company is preparing for potential new product launches and advancing a broad pipeline.

The company said the changes will support both its near-term and long-term objectives.

On May 1, the COVID-19 vaccine maker reported a first-quarter adjusted loss of $1.18 per share, narrower than analysts' expectations for a loss of $3.81. The adjusted figure excludes litigation-related expenses of $2.22 per share.

Revenue totaled $389 million, exceeding the consensus estimate of $227.97 million.

Moderna reiterated its goal of up to 10% revenue growth in 2026, up from $1.94 billion in 2025, and expects the 2026 revenue split to be approximately 50% U.S. and 50% international.

President Stephen Hoge Takes Expanded ...